Abstract
1317P - Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have